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Despite the impact of schizophrenia and mood disorders, which in extreme cases can lead to death, recent decades have brought little
progress in the development of new treatments. Recent studies have shown that Reelin, an extracellular protein that is critical for
neuronal development, is reduced in schizophrenia and bipolar disorder patients. However, data on a causal or protective role of Reelin
in psychiatric diseases is scarce. In order to study the direct influence of Reelin’s levels on behavior, we subjected two mouse lines,
in which Reelin levels are either reduced (Reelin heterozygous mice) or increased (Reelin overexpressing mice), to a battery of
behavioral tests: open-field, black–white box, novelty-suppressed-feeding, forced-swim-test, chronic corticosterone treatment followed
by forced-swim-test, cocaine sensitization and pre-pulse inhibition (PPI) deficits induced by N-methyl-D-aspartate (NMDA) antagonists.
These tests were designed to model some aspects of psychiatric disorders such as schizophrenia, mood, and anxiety disorders. We found
no differences between Reeler heterozygous mice and their wild-type littermates. However, Reelin overexpression in the mouse
forebrain reduced the time spent floating in the forced-swim-test in mice subjected to chronic corticosterone treatment, reduced
behavioral sensitization to cocaine, and reduced PPI deficits induced by a NMDA antagonist. In addition, we demonstrate that while
stress increased NMDA NR2B-mediated synaptic transmission, known to be implicated in depression, Reelin overexpression significantly
reduced it. Together, these results point to the Reelin signaling pathway as a relevant drug target for the treatment of a range of
psychiatric disorders.
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INTRODUCTION
Schizophrenia, mood, and anxiety disorders are devastating
diseases with high prevalence and comorbidity rates
(Altamura et al, 2011; Kessler et al, 2005). Despite the
immense impact of these diseases, knowledge about their
pathophysiology is limited. According to the stress–
diathesis model, these diseases result from interaction
between genetic predisposition and environmental risk
factors. Research into how genetic makeup interacts with
the environmental factors implicated in the triggering of
these diseases is crucial. This implies not only under-
standing the genetic risk factors but also identifying genetic
variations that confer resilience to disease, which may lead
to the development of new treatments.
Reelin, an extracellular protein essential for neuronal
migration and positioning during development (D’Arcangelo
et al, 1995; Tissir and Goffinet, 2003), has received recent
attention because of its connection to bipolar disorder
and schizophrenia. In fact, comprehensive databases of Received 25 March 2011; revised 28 June 2011; accepted 28 June 2011
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(Jia et al, 2010) and the Stanley Foundation Neuropathology
Consortium (Kim and Webster, 2009), place Reelin as a top
candidate gene associated with schizophrenia. This link is
also supported by several studies showing that Reelin levels
are reduced in patients with schizophrenia and bipolar
disorder (Fatemi et al, 2000; Torrey et al, 2005), altered
by antipsychotic, antidepressant, and mood-stabilizing
medication (Fatemi et al, 2009), and also reduced follow-
ing chronic stress (Lussier et al, 2009). Furthermore, Reelin
has also been shown to positively modulate adult-neuro-
genesis (Kim et al, 2002; Pujadas et al, 2010), a process that
when disrupted, has been implicated in cognitive and
mood-related behavior dysfunctions (Zhao et al, 2008).
Noteworthy, several studies found an association between
Reelin variants and schizophrenia or bipolar disorder
in women only (Goes et al, 2010; Liu et al, 2010; Shifman
et al, 2008).
Although these lines of evidence point to a link between
Reelin and psychiatric disorders, other studies do not report
an effect of Reelin’s allelic variants on brain function (Tost
et al, 2010). Moreover, there is scarce direct causal evidence
of the involvement of this protein in these diseases. Reelin-
deficient mice (known as reeler) are not suitable for
behavioral testing because they show severe motor deficits,
and reeler heterozygous mice have been challenged as
a suitable model for psychiatric diseases. While some
studies have shown that heterozygous reeler have cognitive
(Brigman et al, 2006; Qiu et al, 2006a) and sensory-motor
deficits as measured in the pre-pulse inhibition test (PPI)
(Barr et al, 2008; Tueting et al, 1999), others have failed to
find differences (Krueger et al, 2006; Podhorna and
Didriksen, 2004; Salinger et al, 2003).
Reelin participates in several functions that are altered in
psychiatric diseases, such as neuronal development and
synapse formation (D’Arcangelo et al, 1995; Tissir and
Goffinet, 2003), glutamatergic neurotransmission (Herz
and Chen, 2006), Gsk-3b inhibition (Beffert et al, 2002),
and adult neurogenesis (Kim et al, 2002; Pujadas et al,
2010). Given these observations, here we tested whether
varying Reelin levels alters behavioral phenotypes related to
psychiatric disorders (specifically schizophrenia, mood, and
anxiety disorders). For this purpose, we used two mouse
lines, the relatively well-characterized heterozygous reeler
mice (rl/+), and a Reelin overexpressing line (Reelin-OE),
generated in our laboratory (Pujadas et al, 2010) in which
we focused our attention.
Although the design of animal models that relate to all
aspects of a specific psychiatric disease is challenging,
various models (with different levels of etiological, face, and
predictive validity) are available. In this study, we focused
on models that, in addition to presenting predictive validity,
are based on environmental risk factors and thus present
etiological validity, such as chronic stress linked with the
development of ‘helplessness’ and psychostimulant use
(Nestler and Hyman, 2010). In all the tests performed, we
found no differences between rl/+ mice and their wild-type
(WT) littermates, either under basal conditions or after
corticosterone, cocaine or N-methyl-D-aspartate (NMDA)-
antagonist treatments. In addition, we show that increased
Reelin expression does not alter mood-related behaviors
under basal conditions. However, Reelin-OE mice showed
reduced time floating in the forced-swim-test after chronic
stress, reduced sensitization to cocaine, and reduced
disruption of PPI after a NMDA antagonist challenge. In
addition, we demonstrate that while chronic stress in-
creased NMDA NR2B-mediated currents in the hippocam-
pus, which were shown to mediate some of the behavioral
dysfunctions seen after stress (Wong et al, 2007), Reelin
overexpression reduced them. This finding is especially
relevant since it has recently been reported that NR2B
antagonists have antidepressant properties (Li et al, 2010).
SUBJECTS AND METHODS
Animals
Transgenic mice were bred at the Institute for Research in
Biomedicine (Barcelona, Spain). Mice were housed in
groups (2–6 mice per cage) and maintained on a 12-h
light–dark cycle with access to food and water ad libitum.
The Reelin-OE mice used in this study have been described
previously (Pujadas et al, 2010). This line was obtained by
crossing two mouse lines in a tet-off regulated system. The
first line (CamKII/tTA) expresses the tTA transactivator
under the control of the CamKII-a promoter (Mayford et al,
1996). The second line generated in our laboratory contains
a myc-tagged Reelin cDNA construct controlled by a tetO
promoter (tetO-rl). Reeler heterozygous mice were obtained
from Jackson Laboratories (B6C3Fe a/a-Relnrl/J). Mice were
maintained in a C57BL/6J background. Reeler mice were
maintained by crossing rl/+ with C57BL/6J mice. These
mice were backcrossed with C57BL/6J for 410 generations.
CamKII/tTA mice were previously backcrossed into C57BL/
6J for 410 generations in the laboratory of Jesus Avila, who
generously provided us with these mice. They were then
backcrossed with C57BL/6J mice in our laboratory for five
more generations. TetO-rl mice were backcrossed with
C57BL/6J for five generations. All mice were at least 8 weeks
of age at the start of experiments, and behavioral
procedures were conducted during the light phase of the
cycle, except for the self-administration procedure, which
was done in the dark phase. Females were used in the
behavioral experiments, except for the self-administration
experiments in which males where used. A detailed table
with the groups of mice used in each experiment can be
found in the Supplementary information (Supplementary
Table S1). Experiments were conducted blind to the
treatment condition of the mouse, and in compliance with
local animal care protocols.
Immunohistochemistry
For Reelin immunohistochemistry, mice were perfused
transcardially with ice cold 0.1M phosphate-buffered saline
(PBS) and then 4% paraformaldehyde (PFA). Brains were
removed, fixed overnight in PFA, and then transferred to a
30% sucrose solution and stored at 41C. Fifty-micrometer
coronal sections were cut and free-floating sections were
prepared for immunohistochemistry. For immunodetection
of Reelin, sections were blocked for 2h at room temperature
(RT) with PBS-T containing 10% of normal goat serum
(NGS), 0.2% of gelatin and anti-mouse unconjugated F(ab’)2
fragments (1:300, Jackson ImmunoResearch). Anti-Reelin
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overnight at RT with PBS-T with 0.2% gelatin and 5% NGS.
Sections were washed with PBS-T and then incubated for 2h
at RT with biotinylated secondary antibody (1:200, Vector
Laboratories). After subsequent washes with PBS-T, the
sections were incubated for 2h at RT with streptavidin-HRP
(1:400, GE Healthcare UK). After washing, the staining was
revealed using diaminobenzidine (DAB) and H2O2, with
nickel ammonium sulfate added to the solution. Finally,
sections were dehydrated and mounted (Eukitt mounting
medium).
Actimetry Box Test
Locomotor circadian activity was measured in actimetry
boxes (45 45cm; Harvard Apparatus, Panlab, Spain)
placed in a sound-proof cupboard (WT, n¼6; Reelin-OE,
n¼6). Movements were monitored via a grid of infrared
beams and used as an index of locomotor activity (counts).
Counts were integrated every hour and added to obtain total
locomotor activity for a 24-h period, maintaining the 12:12-h
light–dark schedule. All data were collected with Acti-Track
software (Harvard Apparatus).
Corticosterone
Mice were given corticosterone (Sigma, St Louis, MO) in
drinking water (25mg/l) for 3 weeks (Gourley et al, 2008).
Corticosterone was first diluted in ethanol (25mg of corticos-
terone in 2ml of ethanol) before addition to the water. Mice
were tested 1 day after corticosterone treatment (WTReelin OE,
n¼6; Reelin-OE, n¼5; WTrl/+, n¼8;rl/+,n¼12).
Open-Field, Novelty-Suppressed-Feeding, Black and
White Box, and Forced-Swim-Test
General anxiety and depression-like behaviors were tested
using the open-field (OF), novelty-suppressed-feeding
(NSF), black–white box (BW), and forced-swim-test (FST)
tests (Li et al, 2008; Maeng et al, 2008; Santarelli et al, 2003).
The OF test consisted of allowing the mice to explore an
open white arena (50 50cm). The time the mice spent in
the center vs the time in the periphery of the arena as well as
the total distance traveled were recorded over a 10-min trial
(WTReelin OE, n¼26; Reelin-OE, n¼13; WTrl/+, n¼12;rl/+,
n¼12). In the NSF test, mice were deprived of food for 16h
and placed in a well-lit arena (50 50cm, covered with
sawdust) with a food pellet in the center. Latency in feeding
was recorded (WTReelin OE, n¼26; Reelin-OE, n¼13; WTrl/+,
n¼7; rl/+, n¼10). In the BW box test, mice were placed in
the dark compartment of a box (20 20cm) connected to a
well-lit, white compartment (25 25cm). The time the mice
spent in the white compartment was recorded during the
5min of the test (WTReelin OE, n¼12; Reelin-OE, n¼13;
WTrl/+, n¼6; rl/+, n¼6). The FST is a measure of
depression-like behavior and is used to test antidepressant
activity. In the FST, mice were placed for 5min in a 5l
beaker (diameter: 20cm; water depth: 12cm) filled with
warm water (271C) until the 3l mark. The amount of time
the mice spent floating during the last 4min of the trial was
recorded (WTReelin OE, n¼26; Reelin-OE, n¼13; WTrl/+,
n¼6; rl/+, n¼6).
Cocaine Sensitization
Mice used in the OF test were subsequently subdivided and
used in the cocaine sensitization experiment (WTsaline, n¼9;
Reelin-OEsaline, n¼5; WTcocaine, n¼17; Reelin-OEcocaine,
n¼8; WTsaline rl/+, n¼6; rl/+ saline, n¼6W T cocaine rl/+,
n¼6; rl/+ cocaine, n¼6). See Supplementary Table S1 for a
detailed description of the groups of animals used. Thus, the
first day of habituation corresponds to the OF trial. One week
after being subjected to the previous tests, mice were
habituated to the OF box for an additional 20min (habituation
day 2). Starting the following day, separate groups of mice
were injected intraperitoneally with either cocaine (10mg/kg
in 0.9% NaCl) or saline (0.9% NaCl) for 5 consecutive days
and immediately placed in the OF box. Locomotion was
recorded for 20min using the Smart Junior software (Panlab,
Spain). Two weeks after the last cocaine injection, mice
received a challenge injection and were placed back in the OF
box as previously described (Maeng et al, 2008).
Self-Administration
The procedure for cocaine self-administration used in this
work was previously described in detail (Boeuf et al, 2009).
Briefly, mice were anaesthetized and implanted with an
intravenous catheter in the jugular vein. Catheter patency was
e v a l u a t e da tt h ee n do ft h ee x p e r i m e n tb yi n f u s i n g0 . 1m lo f
thiopental (5mg/ml) through the catheter. Mice that did not
show signs of anesthesia 3s after infusion were removed from
the analysis. Three days after surgery, mice were trained to
nose-poke (operant chambers ENV-307A-CT, Med-Associ-
ates) to acquire intravenous self-administration of cocaine
(0.5mg/ml) on a fixed ratio 1 schedule of reinforcement,
during 12 days of daily 1-h sessions (Reelin-OE n¼5; WT
n¼5). The motivational value of cocaine was then assessed
using a progressive ratio schedule of reinforcement (escalated
series: 1-2-3-5-12-18-27-40) in a single 3-h session.
Rotor-Rod
Mice were first habituated for 1min to walk on a rotor-rod
at 4r.p.m. (WT, n¼5; Reelin-OE, n¼5). They were then
given three trials with the rotor-rod accelerating from 4 to
40r.p.m. over 5min. The average latency to fall was
calculated for each mouse.
PPI of Acoustic Startle Response
The PPI of acoustic startle response was measured with a
startle response apparatus (Harvard Apparatus). Each
mouse was habituated to the equipment by being placed
in the restraint device for 5 in a day during 3 days. On the
test day, mice were allowed a 15-min habituation to the
apparatus with background noise of 62dB and then
exposed to six blocks of seven trial types in pseudo-random
order with 30-s inter-trial intervals. The eight trial types
were as follows: trial 1 (startle-only trial), 40ms of a 120dB,
8000Hz sound; trials 2–7 (pre-pulse (PP) trials), 40ms of a
120dB, 8000Hz sound preceded for 140ms by a 20ms PP
sound of 70, 74, 78, 82, 86, or 90dB; and trial 8, 62dB
background noise. The startle response was recorded
for 65ms, with measurements every 1ms from the onset
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recorded during the 65ms sampling window was used as the
dependent variable. The PPI for each PP trial was defined as
100 ((startle amplitude on PP trials/startle amplitude on
pulse alone trials)   100). One week after baseline PPI
testing, the mice were injected with MK-801 (0.15mg/kg in
0.9% NaCl) and then retested for PPI 10min later. One week
later, the same group was tested after a 0.3mg/kg MK-801
injection (WTReelin OE, n¼7; Reelin-OE, n¼10; WTrl/+,
n¼9; rl/+, n¼9).
Electrophysiology
Transverse brain slices (400mm thickness) were prepared as
described previously (Martin and Buno, 2003) and incubated
for 41h at RT (21–241C) in ACSF. The ACSF contained the
following (in mM): NaCl 124, KCl 2.69, KH2PO4 1.25, MgSO4 2,
NaHCO3 26, CaCl2 2 and glucose 10, and was gassed with 95%
O2 and 5% CO2. Slices were transferred to an immersion
recording chamber and superfused (2.5ml/min) with equili-
brated ACSF. Extracellular field excitatory postsynaptic poten-
tials (fEPSPs) were recorded with a glass microelectrode
(impedances: 2–3MO; filled with 1M NaCl) positioned in
stratum radiatum area CA1. Evoked fEPSPs were elicited by
stimulation of the Schaeffer collateral fibers with an extra-
cellular bipolar nichrome electrode via a 2100 isolated pulse
stimulator (A-M Systems, Carlsborg, WA). The responses to
paired-pulse stimulation at a range of interpulse intervals (25–
400ms) were used to measure paired-pulse facilitation. Data
were transferred to the hard disk of a Pentium-based computer
using a DigiData 1440A interface and the pCLAMP 10.0
software (Molecular Devices, Union City, CA). To measure the
contribution of NMDA receptors to fEPSPs, we performed the
experiment in the presence of 50mM bicuculline to isolate
EPSPs from gamma-aminobutyric acid A-mediated inhibitory
synaptic transmission. Application of AP5 (50mM), an
antagonist of NMDARs, abolished fEPSPs, thereby confirming
that the fEPSPs recorded were mediated through NMDARs. In
this condition, 6- cyano-7-nitroquinoxaline-2, 3-dione (CNQX;
20mM) in Mg2+-free external solution was added to
pharmacologically isolated NMDA fEPSC components. Train
stimuli at 100Hz were used to assess the synaptic activation of
the NMDA receptors by high-frequency afferent stimulation.
To measure the contribution of NR2B receptors, we performed
recordings in the presence of 3mM of Ifenprodil. All drugs were
purchased from Sigma, except CNQX, DL-2-amino-5-phos-
phopentanoic acid (AP5), Ifenprodil and Bicuculline, which
were all from Tocris Cookson (Bristol, UK).
Statistical Analysis
Statistical differences were established using a two-tailed
Student’s t-test or ANOVA followed by an LSD post hoc test.
Data are expressed as mean±SEM.
RESULTS
Reeler Heterozygous Mice Do Not Exhibit Behavioral
Phenotypes Related to Psychiatric Disorders
Contradictory findings have been reported regarding beha-
vioral alterations of Reeler heterozygous mice (Barr et al,
2008; Brigman et al, 2006; Krueger et al, 2006; Podhorna
and Didriksen, 2004; Qiu et al, 2006a; Salinger et al, 2003;
Tueting et al, 1999). In order to assess whether these mice
present behavioral alterations related to psychiatric dis-
orders, we first subjected them to a battery of tests currently
used as anxiety (OF, NSF, and BW box) and depression
(FST) models. Heterozygous reeler mice (rl/+) showed no
significant differences from their WT littermates in any of
the tests performed (Figures 1a–e).
Although diseases like schizophrenia and bipolar dis-
order have a significant heritable component, interactions
between genes and environmental risk factors make a sig-
nificant contribution to the development of these diseases.
One of the major environmental factors that precipitates
depression as well as schizophrenic and bipolar disorder
episodes is stress (Krishnan and Nestler, 2008). In order to
study stress-associated behavioral dysfunctions in mice,
we subjected them to a chronic treatment of the stress-
associated hormone corticosterone. Next, we used the FST
as a measure of developed helplessness-like behavior
(Gourley and Taylor, 2009). After 3 weeks of corticosterone
administration, there were no differences between stressed
WT and heterozygous reeler mice (Figure 1f).
Dopamine agonists and NMDA antagonists induce behav-
ioral dysfunctions, such as PPI and working-memory
deficits, similar to those observed in schizophrenia (Geyer
and Markou, 1995; Krystal et al, 1994). In addition, the
hypothesis that schizophrenia might be related to dopami-
nergic or glutamatergic dysfunction (Belforte et al, 2009) led
to the development of mouse models based on the
modulation of these neurotransmitters (Geyer and Markou,
1995; Nestler and Hyman, 2010). Locomotion sensitization to
psychostimulants provides a good predictive value of the
efficacy of antipsychotic and mood-stabilizing drugs and this
approach has been used in schizophrenia and mania research
(Geyer and Markou, 1995; Nestler and Hyman, 2010). In order
to study manic-like behavior and positive symptoms of
schizophrenia in mice, we used the cocaine sensitization
model (Figures 1g–h). Heterozygous reeler mice receiving
saline treatment had locomotion values similar to those of
their WT littermate controls throughout the experiment
(Figure 1g). As expected, cocaine-treated rl/+ and WT mice
increased their locomotion over the course of the treatment,
and we found no significant differences between genotypes
(Figure 1h; day: F(7,70)¼8.54, po0.001). A comparison of
locomotion on day 19 between all the groups indicated that
animals receiving cocaine showed higher locomotion values,
independently of the genotype (drug: F(1,19)¼11.49, po0.01;
LSD test po0.01).
Deficits in PPI may indicate an incapacity to filter
irrelevant information and they are observed in schizo-
phrenic patients (Braff et al, 2001). Thus, PPI has been used
as a tool to study schizophrenic-related behavior in mice as
it shows good face and predictive value (Geyer and Markou,
1995; Miyakawa et al, 2003). In addition, previous studies
have shown that heterozygous reeler mice present PPI
deficits (Barr et al, 2008). We thus examined whether PPI
was modified in heterozygous reeler mice. No significant
disruption of PPI in untreated rl/+ was detected when
compared with their WT littermate controls (Figures 1i–j
and Supplementary Figure S3a). Startle amplitudes are
shown in Supplementary Figure S2.
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model of the positive symptoms of schizophrenia and have
good predictive value of the efficacy of anti-psychotic
medication (van den Buuse, 2010). Here, we proceeded to
treat rl/+ mice and their respective WT littermates with the
NMDA antagonist, MK-801, 10min before testing them for
PPI. MK-801 disrupted PPI in a dose-dependent manner in
WT (Figure 1i) and rl/+ animals (Figure 1j). In rl/+ WT
littermates, there was a significant dose by PP level
interaction, showing that PPI was significantly disrupted
when using 0.3mg/kg of MK-801 on the PP levels of
78–86dB (PP dose: F(10,120)¼2.96, po0.01; LSD test,
po0.05). At 0.3mg/kg, MK-801 also significantly disrupted
PPI in rl/+ mice (dose: F(2,24)¼9.72, po0.0001; LSD test
po0.05). Together, these results suggest that reeler hetero-
zygous mice do not show behavioral alterations related to
psychiatric disorders.
Reelin-OE Mice Display Normal Anxiety- and
Depression-Related Behaviors Under Basal Conditions
Given that rl/+ mice fail to show behavioral alterations, we
tested whether Reelin overexpression is involved in the
modulation of schizophrenia-, mood-, and anxiety-related
behavioral phenotypes. For this purpose, we used a line
generated in our laboratory (Pujadas et al, 2010) that
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Figure 1 Behavioral characterization of reeler heterozygous (rl/+) mice (a–e) Characterization of anxiety- and depression-like behaviors in rl/+ mice.
There were no significant differences between rl/+ and WT mice in the distance travelled (a) and in the time spent in the center (b) in the open-field test
(OF). Nor there were differences in the latency to feed in the novelty-suppressed feeding test (c: NSF), in the time spent on the white compartment of the
black and white box (d: BW) or in the time spent floating in the forced-swim-Test (e: FST). (f) After 3 weeks of corticosterone administration, there were no
significant differences in the time spent floating in the FST between rl/+ and WT mice. (g, h) Cocaine sensitization in rl/+ mice. (g) Locomotion values for
rl/+ and WT mice treated with saline. (h) Sensitization to continuous cocaine administration in rl/+ and WT mice. (i) Reelin heterozygous WT littermate
controls showed significantly reduced PPI after treatment with 0.3mg/kg MK-801 at PP levels of 78–86dB. (j) There was a significant effect of the dose on
the disruption of PPI in rl/+ mice. PPI was significantly disrupted with the 0.3mg/kg dose (#). In figure (j), there was a significant effect of the dose, as shown
by ANOVA. A posterior LSD test showed that the 0.3mg/kg dose was significantly different from the other treatments. Significant differences were
established at *po0.05. Data are presented as mean±SEM.
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promoter (Reelin-OE). This promoter drives expression
exclusively in the postnatal brain in excitatory forebrain
neurons. These animals showed widespread expression of
Reelin in pyramidal neurons of the neocortex and
hippocampus, as well in most striatal neurons (Figures 2a
and b). We have previously shown that this 4–6-fold
increase in Reelin expression leads to over-activation of the
Reelin pathway, as seen by an increase in Dab1 phosphor-
ylation (Pujadas et al, 2010). In contrast to the dramatic
cytoarchitectonic alterations and severe motor deficits
found in reeler mice (Reelin knock-out), no gross anatomic
or behavioral abnormalities were observed in Reelin-OE
mice. These mice showed increased activity during the dark
phase of their circadian rhythm (Figure 2c; 22–8h:
t(10)¼ 2.40, po0.05) and normal locomotion in the OF
test (Figure 2d), thereby indicating the absence of motor
deficits.
Next, we tested whether anxiety-related behaviors were
altered in the Reelin-OE mice. We found no differences
between Reelin-OE mice and their littermate controls in the
OF (Figures 2d and e), in the NSF (Figure 2f) or in the FST
(Figure 2h). However, Reelin-OE animals showed reduced
anxiety-like behavior in the BW box (Figure 2g;
t(23)¼ 2.27, po0.05).
Reelin-OE Mice Show Reduced Time Floating in the FST
After Chronic Corticosterone Treatment and also
Hyperlocomotion Induced by Psychostimulants
To test whether environmental risk factors like stress and
psychostimulant abuse affect Reelin-OE mice differently, we
next tested these mice in the FST after chronic corticoster-
one treatment and in the cocaine sensitization model.
Corticosterone-treated WT mice spent more time floating in
the FST than controls. This effect was abolished by Reelin
overexpression, thereby indicating that Reelin-OE mice
were less susceptible to corticosterone-induced helpless-
ness-like behavior (Figure 3a; genotype treatment:
F(1,27)¼7.04, po0.05; LSD test po0.05). These data suggest
that Reelin overexpression protects against the development
of behavioral dysfunctions induced by chronic stress.
In the cocaine sensitization model, no differences in
locomotion were observed between the Reelin-OE and WT
mice receiving saline injections. This observation indicates
that there were no differences in novelty-induced hyperlo-
comotion or in habituation to the novel environment
(Figure 3b). On the first day of sensitization, cocaine-
injected Reelin-OE mice exhibited locomotion values
identical to those of WT and Reelin-OE animals injected
with saline (Figures 3c and d). In contrast, WT mice
injected with cocaine showed significantly higher locomo-
tion values than all the other groups (genotype drug:
F(1,35)¼4.92, po0.05; LSD test po0.05). Over the course of
the experiment, WT mice injected with cocaine showed a
dramatic increase in locomotion activity. In contrast,
Reelin-OE mice showed less sensitivity to continued cocaine
administration than their WT littermates (Figure 3e;
genotype day: F(7,161)¼11.80, po0.0001; LSD test
po0.05). Comparison of the locomotion values at day 19
between cocaine- and saline-treated animals shows that
cocaine-treated WT mice presented significantly higher
locomotion values than saline controls and cocaine-treated
Reelin-OE mice (Figure 3f; genotype drug: F(1,35)¼5.99,
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Figure 2 General characterization of Reelin-OE mice. (a, b) Reelin expression in Reelin-OE mice (b) was higher than in WT mice (a) throughout the
postnatal forebrain, including the hippocampus (CA1, CA3, DG) and the cortex (NC). ArrowheadsFReelin overexpressing neurons. Scale bar: 500mm.
Scale bar of insets: 100mm. (c) Reelin-OE mice showed increased activity during the dark phase of the light cycle. (d–h) Characterization of anxiety- and
depression-like behaviors in Reelin-OE mice. There were no significant differences between WT and Reelin-OE mice in most tests (d–e: OF; f: NSF; h: FST).
Reelin-OE mice spent significantly more time in the white compartment in the Black–White box test (g: BW). Significant differences were established at
*po0.05. Data are presented as mean±SEM.
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Neuropsychopharmacologypo0.05; LSD test po0.05). These findings indicate that the
behavioral dysfunctions induced by cocaine were dramati-
cally blocked by Reelin overexpression. The differences
observed in cocaine sensitization were not due to differ-
ences in the rewarding effects of cocaine or in motor
performance, measured in the cocaine self-administration
paradigm and in the rotor-rod, respectively (Supplementary
Figures S1a–c in Supplementary information).
Taken together, these data show that Reelin-OE mice are
resistant to the psychomotor effects of chronic psycho-
stimulant administration.
Reelin-OE Prevents PPI Deficits Induced by NMDA
Antagonists
PPI deficits are an especially relevant schizophrenia
endophenotype given that they can be easily tested in mice.
We found no differences in PPI between untreated WT and
Reelin-OE mice (Figures 4a and b and Supplementary
Figure S3d). Startle amplitudes are shown in Supplementary
Figure S2. However, significantly lower PPI levels were
observed in WT mice (Reelin-OE littermates) treated with
0.3mg/kg of MK-801 compared with the control and the
0.15mg/kg groups (Figure 4a; dose: F(2,18)¼4.01, po0.05;
LDS test po0.05), while no differences between treated and
control Reelin-OE were detected (Figure 4b). This finding
indicates that Reelin-OE mice are more resilient to a NMDA
antagonist challenge. This observation is highly relevant
because this test has good predictive value for the efficacy of
antipsychotic medication (van den Buuse, 2010).
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Figure 3 Reduced helplessness-like behavior after corticosterone treatment and cocaine sensitization in Reelin-OE mice. (a) Reelin-OE mice spent less
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Figure 4 Increased resilience after a MK-801 challenge in Reelin-OE
mice. (a) PPI in WT mice (Reelin-OE littermates) was significantly disrupted
at a dose of 0.3mg/kg (#). In figure (a), there was a significant effect of the
dose, as shown by ANOVA. A posterior LSD test showed that the 0.3mg/kg
dose was significantly different from the other treatments. (b) MK-801
treatment did not affect PPI in Reelin-OE mice. Data are presented as
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Reelin overexpression and behavioral phenotypes
CM Teixeira et al
2401
NeuropsychopharmacologyReelin Increases Glutamatergic Transmission In Vivo
Reelin controls glutamatergic neurotransmission during
development (Chen et al, 2005; Groc et al, 2007; Herz and
Chen, 2006; Qiu et al, 2006b) and LTP is enhanced in
Reelin-OE mice (Pujadas et al, 2010). Given that NMDA
receptor hypofunction is often observed in schizophrenic
patients (Coyle, 1996), we proceeded to analyze NMDA-
mediated transmission in Reelin-OE mice. We first analyzed
basal synaptic transmission in acute hippocampal slices
from these mice and WT littermates. After stimula-
ting Schaeffer collaterals with isolated stimuli of increasing
intensity, neurons were recorded in the CA1 region.
Extracellular field recordings showed that Reelin-OE CA1
neurons exhibited increased fEPSP responses, which were
statistically significant at high stimulus strengths (Figure 5a;
V20: t(20)¼ 2.18, po0.05; See also Supplementary Figure
S4 in Supplementary information). Using fEPSP record-
ings evoked by a three-stimulus train (100Hz), we next
examined whether synaptic activation of NMDA receptors
was normal in Reelin-OE mice. After the second and third
stimuli in the train, the NMDA receptor-mediated compo-
nent of fEPSP (pharmacologically isolated) was significantly
reduced in the WT slices when compared with the
first stimuli (Figure 5b; t(6)¼3.83, po0.01). In contrast,
there was a significant increase after the second stimulus
in the Reelin-OE mice (Figure 5b; t(5)¼ 2.61, po0.05).
These observations indicate that Reelin overexpression
potentiates NMDA-dependent glutamatergic neurotrans-
mission, a process that is altered in several psychiatric
disorders (Coyle, 1996).
Reelin Decreases NMDA NR2B-Mediated Currents
Reelin is involved in the NR2B to NR2A developmental
switch (Groc et al, 2007). Given that NR2B antagonists
act as antidepressant drugs (Li et al, 2010), we next
studied NR2B activity in WT and Reelin-OE mice. Perfusion
of Ifenoprodil, a specific NR2B antagonist, reduced
Figure 5 Reelin overexpression modifies synaptic activation of NMDA receptors and the function of NR2B subunit. (a) fEPSP slopes for WT (filled circle,
n¼12 slices from three mice) and Reelin-OE (open circle, n¼10 slices from three mice) slices for a given range of stimulus intensities. Note that Reelin-OE
CA1 neurons tended to exhibit increased fEPSP responses. Inset shows representative fEPSPs recorded in the stratum radiatum, and evoked by stimulation
of the Schaffer collateral-commissural pathway with different intensities in WT (top) and Reelin-OE (bottom) mice. (b) Summary data showing mean
NMDA-isolated fEPSP slopes in WT (filled bar; n¼7 slices from three mice) and Reelin-OE (open bar; n¼6 slices from three mice) slices. The fEPSP slope
was significantly smaller in the WT mice for the third stimulus and significantly larger in the Reelin-OE mice for the second stimulus (compared with its
respective first stimulus). Significant differences were established at *po0.05 and **po0.01. Inset shows representative field responses of NMDA
component evoked by a 100Hz train (three stimuli) in WT (top trace) and Reelin-OE (bottom trace), recorded in the presence of 20mM CNQX to block
the AMPA component. Calibration: 0.5mV, 10ms. (c) Time course of 3mM Ifenprodil effects on normalized mean NMDAR-mediated fEPSP slopes evoked
by Schaeffer collateral stimulation in WT control (filled square, n¼6 slices from three mice), WT treated with corticosterone (open square, n¼6 slices from
three mice), Reelin-OE control (filled circles, n¼6 slices from three mice), and Reelin-OE treated with corticosterone (open circles, n¼6 slices from three
mice) slices. Inset shows representative fEPSPs recorded in the absence or presence of Ifenprodil. Significant differences were established at **po0.01 and
***po0.001 (with respect to pre-Ifenprodil perfusion baseline slope values) and
#po0.05 (between WT and Reelin-OE treated with corticosterone). Data
are presented as mean±SEM.
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(t(5)¼3.35, po0.01) while no changes were detected in
Reelin-OE slices (Figure 5c). These observations indicate
that Reelin overexpression in vivo leads to a dramatic
hypofunction of NR2B-containing NMDARs.
Next, we analyzed NMDA-mediated neurotransmission in
WT and Reelin-OE mice treated with corticosterone
(Figure 5c; see also Supplementary Figure S5 in Supple-
mentary information). In corticosterone-treated WT mice,
electrophysiological recordings in the presence of Ifenprodil
showed a marked reduction in NMDARs-mediated fEPSPs
(nearly 50% of baseline; Figure 5c; t(5)¼6.96, po0.001).
Interestingly, Reelin-OE mice treated with corticosterone
exhibited fEPSPs that were indistinguishable from those of
WT controls (Figure 5c; t(10)¼ 2.39, po0.05). Given that
NR2B is upregulated after stress and NR2B inhibition is
sufficient to prevent behavioral deficits induced by stress
(Li et al, 2010; Wong et al, 2007), our results suggest that
Reelin overexpression increases resilience to stress through
NR2B downregulation.
DISCUSSION
In order to study the role of Reelin in the modulation of
behavioral phenotypes related to schizophrenia, mood,
and anxiety disorders, we used two mouse lines that
express different levels of Reelin: Reelin overexpressing
mice (Reelin-OE) and heterozygous Reelin knock-out mice
(rl/+). Under basal conditions, Reelin-OE and rl/+ mice
presented mood-related behaviors similar to those of
WT mice. However, when challenged with environmental
stressors implicated in the genesis of psychiatric disea-
sesFchronic stress and psychostimulant abuseFReelin-
OE mice were more resilient. These mice spent less time
floating in the FST after chronic corticosterone treatment
and less hyperlocomotion induced by cocaine. Furthermore,
they were protected against the PPI deficits induced
by NMDA antagonists. In addition, we show that Reelin
overexpression enhanced glutamatergic transmission while
simultaneously reducing NR2B-subunit-dependent NMDA
currents.
Intense research effort is underway to identify resilience
and risk factors involved in the pathophysiology of
psychiatric diseases. Although epidemiological studies
provide us with a list of candidate genes, further studies
are necessary to identify whether these genes have a
causative or protective role or even no role at all. Previous
studies have shown that Reelin, an extracellular protein
extensively studied during development because of its roles
in cortical lamination, is downregulated in patients with
several psychiatric diseases and is associated with schizo-
phrenia (Fatemi et al, 2000; Jia et al, 2010; Kim and
Webster, 2009). However, behavioral studies on the
function of this protein have been hampered by the fact
that reeler mice have severe motor deficits. In fact, the
absence of Reelin in humans causes a neurological
disorderFlissencephalyFcharacterized by the lack of
development of the brain gyri and sulci, which leads to
severe neurological impairments (Hong et al, 2000). In
contrast, reeler heterozygous mice, which have no motor
deficits (Podhorna and Didriksen, 2004), have been studied
in some detail. These mice have mild cognitive deficits
and higher anxiety levels, with PPI deficits being the most
consistently documented behavioral phenotype related to
psychiatric diseases (Barr et al, 2008; Tueting et al, 1999).
However, these findings have not been replicated by other
studies (Podhorna and Didriksen, 2004; Salinger et al,
2003). Furthermore, to our knowledge, there is no strong
evidence of depression-like or manic-like behavioral
phenotypes in these mice. As most studies in rl/+ mice
have been conducted under basal conditions, we tested
whether environmental stressors could uncover a behavior-
al phenotype. However, we found no differences between
reeler heterozygous and WT mice in any of the paradigms
tested. The absence of difference could be attributable to
compensatory effects that commonly prevent the develop-
ment of a phenotype in heterozygous mice. To overcome
this, it would be interesting to repeat these behavioral tests
in Reelin conditional knock-out mice. Our results are
consistent with those of several other studies reporting no
differences between rl/+ and WT mice in the OF and BW
tests (Podhorna and Didriksen, 2004) and in the FST with or
without corticosterone treatment (Lussier et al, 2010). It is
worth noting that discrepancies in the detection of PPI
deficits in the rl/+ might result from differences in the
experimental setup as referred to in (Barr et al, 2008). In
that study, the investigators show deficits in cross-modal
PPI in rl/+ but no deficits in acoustic PPI, the procedure we
used. In our study, in addition to following a down-
regulation strategy, we also studied the function of Reelin
using the reverse approach, that is, Reelin overexpression.
Using this novel approach, not only did we overcome the
motor deficits found in the reeler mice but we also show
a potential therapeutic use of Reelin pathway activa-
tion. Interestingly, Reelin overexpression had only a mild
effect on anxiety-related behaviors under basal conditions
(a reduction of anxiety-like behavior in the BW box).
Psychiatric disorders are believed to result from a
combination of genetic and environmental factors. There-
fore, we proceeded to test whether Reelin protects against
environmental insults. After exposure to chronic corticos-
terone treatment (a stress-associated hormone), Reelin-OE
mice spent less time than WT mice floating in the FST,
a paradigm that intents to model the development of
helplessness behaviorFcharacteristic of depression in
humansFafter chronic stress, and that has predictive value
for the efficacy of antidepressants. In addition, in the
presence of Ifenprodil (NR2B antagonist), slice recordings
from corticosterone-treated WT animals showed a signifi-
cantly higher reduction in fEPSPs than those of non-
stressed WT animals. In contrast, fEPSPs of corticosterone-
treated Reelin-OE mice slices were similar to those of WT
non-stressed controls. Given that NR2B antagonists act as
antidepressants (Li et al, 2010), we propose that Reelin may
increase resilience to stress-induced behavioral dysfunc-
tions through the downregulation of NR2B-mediated
transmission.
Diseases like schizophrenia, mood, and anxiety disorders
have high comorbidity levels. For instance, it has been
reported that depression has a prevalence of 50% over
the lifetime of schizophrenic patients (Altamura et al,
2011). Interestingly, we found that Reelin overexpression
not only prevents behavioral dysfunctions after chronic
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tion induced by cocaine and PPI deficits induced by MK-
801. Both of these testsFcocaine-induced hyperlocomo-
tion and PPI deficits induced by NMDA antagonistsFare
used as models of positive symptoms of schizophrenia
(Geyer and Markou, 1995; van den Buuse, 2010) and show
predictive validity of the effects of antipsychotic and mood-
stabilizing medication, as well as face validity in the case of
PPI deficits (Geyer and Markou, 1995; Nestler and Hyman,
2010). It is fairly well established that the Reelin signaling
pathway leads to Gsk-3b phosphorylation at Ser9, thereby
leading to its enzymatic inhibition (Beffert et al, 2002).
Several studies have reported that other candidate genes
for mental illness, such as DISC1 (Mao et al, 2009) and
Neuregulin 1 (Fazzari et al, 2010), regulate behavior
through Gsk-3b inhibition. It is therefore possible that
some of the behavioral effects of Reelin overexpression are
due to Gsk-3b inhibition. In fact, lithium, a Gsk-3b inhibitor
commonly used to treat bipolar disorder, also decreases
psychostimulant-induced hyperlocomotion (Beaulieu et al,
2009).
In summary, here we show that the overexpression of
Reelin in the mouse forebrain protects against the effects of
chronic corticosterone and psychostimulant treatments.
These observations indicate that this pathway may be an
important therapeutic drug target.
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